To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer
A randomized, multi center, open label, two-period, single dose, crossover study to evaluate the bioavailability and safety of Paclitaxel Injection Concentrate for Suspension in Locally Recurrent or Metastatic Breast Cancer subjects.
Metastatic Breast Cancer|Locally Recurrent Cancer
DRUG: PICS (Reconstitution Method 1 or 2)
Maximum observed plasma concentration Plasma, 8 weeks|area under the plasma concentration versus time curve, from time 0 to the last measurable concentration, 8 weeks|area under the plasma concentration versus time curve from time 0 to infinity, 8 weeks|Incidence of Treatment-Emergent Adverse Events, shall be coded per CTCAE, Version 5.0, 8 weeks
A randomized, multi center, open label, two-period, single dose, crossover study to evaluate the bioavailability and safety of Paclitaxel Injection Concentrate for Suspension in Locally Recurrent or Metastatic Breast Cancer subjects.